BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, May 28, 2026
Home » Topics » Disease categories and therapies » Genetic/congenital

Genetic/congenital
Genetic/congenital RSS Feed RSS

Genetic/congenital

SGT-212 restores FXN function in Friedreich’s ataxia models

March 11, 2026
No Comments
Friedreich’s ataxia (FA) is an inherited neurodegenerative disorder caused by GAA repeat expansions in the FXN gene, which produces a mitochondrial protein vital for iron-sulfur cluster assembly and energy metabolism. Researchers at Solid Biosciences Inc. presented preclinical data supporting the first-in-human trial on SGT-212 gene therapy in FA models.
Read More
Illustration of X chromosomes with DNA
Genetic/congenital

Alternative splicing strategy shows promise for Rett syndrome

March 4, 2026
By Mar de Miguel
No Comments
A therapeutic strategy based on alternative splicing of the MECP2 gene could restore protein levels in Rett syndrome, a neurological disorder caused by mutations in that gene. Scientists at Baylor College of Medicine have successfully tested this approach both in vitro in neurons from Rett patients that produce some functional protein, correcting the altered gene expression and improving neuronal functions, and in vivo in mice.
Read More
Hematologic DNA blood test
Endocrine/metabolic

Beam Therapeutics reveals new program for PKU

Feb. 27, 2026
No Comments
Beam Therapeutics Inc. has added a new program to its liver-targeted genetic disease franchise, BEAM-304, for the treatment of phenylketonuria (PKU).
Read More
Neurology/psychiatric

Brain-targeted AAV gene therapy shows promise for CLN5 disease in mice

Feb. 19, 2026
No Comments
Researchers from University College London and collaborating institutions have recently published results from their study aiming to optimize gene therapy for CLN5 disease.
Read More
Genetic/congenital

Inventisbio discovers PI3Kα mutant inhibitors

Feb. 17, 2026
Inventisbio Co. Ltd. and Inventisbio LLC have divulged compounds acting as phosphatidylinositol 3-kinase α (PI3Kα) E545K mutant inhibitors.
Read More
Art concept for gene therapy research
Endocrine/metabolic

Anti-tFR1 nanobody-I2S gene therapy corrects Hunter syndrome neuropathy in mice

Feb. 17, 2026
No Comments
Hunter syndrome, also called mucopolysaccharidosis II, is an X-linked genetic lysosomal disorder caused by loss-of-function mutations in the IDS gene, encoding iduronate-2-sulfatase (I2S). I2S is a lysosomal enzyme responsible for the cleavage of glycosaminoglycans (GAGs), and its deficiency results in accumulation of GAGs leading to a multisystemic disorder.
Read More
Optogenetics illustration
Ocular

New models, gene therapy approach for ocular phenotype of Friedreich’s ataxia

Feb. 12, 2026
No Comments
Friedreich’s ataxia (FA), the most common form of hereditary ataxia, is an autosomal recessive neurodegenerative disorder affecting multiple organ systems, and causing cardiomyopathy, scoliosis, muscle weakness, speech impairment and other systemic issues.
Read More
3D illustration of platelets in the boodstream
Hematologic

Tangram’s TGM-148 demonstrates pan-bleeding disorder therapeutic potential

Feb. 6, 2026
No Comments
Researchers at Tangram Therapeutics Inc. have presented preclinical safety and efficacy data for TGM-148 in a model of von Willebrand disease.
Read More
Illustration of cancer inside colon
Cancer

Study uncovers pathogenic variants of Lynch syndrome

Jan. 21, 2026
By Mar de Miguel
No Comments
A new method, based on gene editing with oligonucleotides and functional analyses, identifies which variants of DNA repair genes associated with Lynch syndrome are truly harmful and which are not. Scientists at The Netherlands Cancer Institute have developed this technique and classified these gene variants in both coding and noncoding regions, distinguishing those that are pathogenic from those that are benign.
Read More
Pediatric brain illustration
Genetic/congenital

Succinate prodrug NV-354 protects the brain in complex I deficiency

Jan. 20, 2026
No Comments
Leigh syndrome is a fatal pediatric neurodegenerative disorder caused by mitochondrial dysfunction, most often due to defects in the mitochondrial respiratory chain. The Ndufs4 knockout (Ndufs4 KO) mouse is an established model of the disease, as loss of the NDUFS4 subunit leads to complex I (CI) deficiency and reproduces the neurological decline and pathology seen in affected children. Researchers from The Children’s Hospital of Philadelphia Research Institute and collaborators described how NV-354, a water-soluble prodrug of succinate, may mitigate this mitochondrial dysfunction.
Read More
Previous 1 2 3 4 5 6 7 8 9 … 42 43 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 27, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 26, 2026
  • Microscopy of a cross-section of mouse skin containing melanoma tumors

    Researchers identify innate immune barrier against melanoma

    BioWorld
    Australian researchers have identified a previously overlooked population of immune cells in the skin that physically restrain melanoma growth by engulfing live...
  • In the clinic for May 26, 2026

    BioWorld
    Clinical updates for biopharma and med tech, including data readouts and publications: 858, A2 Biotherapeutics, AC Immune, Agendia, Agenus, Aktis, Ascentage,...
  • Cavalon Therapeutics and Northwestern patent new Cav1.3 blockers

    BioWorld Science
    Cavalon Therapeutics Inc. and Northwestern University have disclosed new voltage-gated calcium channel Cav1.3 blockers potentially useful for the treatment of...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing